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ABSTRACT
Although results of autologous stem cell transplantation (SCT) for recurrent follicular non-Hodgkin lym-
phoma (NHL) have been previously reported, the long-term results and evaluation of prognostic factors in
a large patient population receiving this therapy are difficult to find in the literature. To address these issues,
we evaluated 248 patients with recurrent follicular NHL treated with high-dose chemotherapy and autolo-
gous SCT between 7/87 and 6/03. According to the World Health Organization (WHO) classification system,
64 patients (26%) had follicular NHL grade 1 (FL 1), 98 (40%) had FL 2, and 86 (35%) had FL 3. At the time
of transplantation, 88 of the patients (35%) had a Follicular Lymphoma International Prognostic Index
(FLIPI) score of low risk, 87 (35%) had an intermediate-risk FLIPI score, 37 (15%) had a high-risk FLIPI
score, and 36 (15%) had at least 1 missing value, preventing calculation of the FLIPI score. The 5-year overall
survival (OS) for all patients was 63%, and the 5-year progression-free survival (PFS) was 44%. In a multivar-
iate analysis, a histological grade of FL 3, a high-risk FLIPI score at the time of transplantation, and having
received 3 or more previous chemotherapy regimens were significant factors for predicting a worse OS. In
addition, the use of a transplantation regimen including a monoclonal antibody decreased the relative risk
of progressive lymphoma. These data suggest that transplantation earlier in the course of the disease for
patients with follicular lymphoma with use of a monoclonal antibody–based regimen may lead to improved
outcomes.
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Although patients with grades 1 and 2 follicular
non-Hodgkin lymphoma (NHL) typically have an in-
dolent clinical course, the disease is not believed to be
curable with standard chemotherapy or monoclonal
antibodies (mAb). Most patients can experience pro-
longed remissions with combination chemotherapy
with or without immunotherapy [1-4]. However,
once a patient relapses after initial therapy, the time
that the patient stays in remission with each subse-36quent therapy typically decreases from the previous re-
mission duration [5].
Numerous treatment options are available for re-
current follicular NHL are numerous, and the optimal
therapy is unknown. The role of high-dose chemo-
therapy and autologous stem cell transplantation
(SCT) for recurrent follicular NHL remains contro-
versial. Although several phase II trials have reported
outcomes of patients with recurrent follicular NHL
receiving this therapy [6-9], only 1 phase III trial
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the CUP trial [10]—has been published. These trials
support the position that high-dose chemotherapy in
chemosensitive follicular lymphoma (FL) patients
may improve the progression-free survival (PFS) com-
pared with conventional chemotherapy in historical
controls [6-9] or matched controls in the case of the
CUP trial [10]. However, in some of these trials, ad-
vantages in overall survival (OS) are more difficult to
discern compared with historical controls [7]. Deter-
mining the patient population most likely to benefit
from this type of intense therapy may improve the out-
look for patients with recurrent follicular NHL and
spare others from toxicity if this therapy is less likely
to be beneficial. In addition, few studies have addressed
the long-term results of autologous SCT in a large
group of FL patients. Therefore, we evaluated 248 pa-
tients with recurrent FL in a multivariate analysis of
factors predicting for improved OS, PFS, and
decreased progression rates after high-dose chemo-
therapy and autologous SCT.
PATIENTS AND METHODS
Patients
A total of 248 patients with recurrent follicular
NHL who received high-dose chemotherapy and au-
tologous stem cell transplantation at the University
of Nebraska Medical Center were identified in the
clinical database. All of the patients underwent trans-
plantation between July 1987 and June 2003 and re-
ceived a high-dose chemotherapy regimen that was
in effect at the time of their transplantation. All pa-
tients received an unpurged autologous stem cell or
bone marrow product according to standard tech-
niques described previously. All patients signed a valid
informed consent for their therapy, and all studies
were approved by the Scientific Review Committee
and the Institutional Review Board of the University
of Nebraska Medical Center (UNMC) and the
UNMC/Eppley Cancer Center.
Data Collection and Review
Hospital, clinic, and follow-up notes were re-
viewed for patient and transplant characteristics in
the pretransplantation, transplantation, and post-
transplantation time frames. All patients had a central
pathology review at UNMC and were classified as
follicular grade 1, 2, or 3 according to the World
Health Organization (WHO) criteria [11]. Excisional
biopsy specimens obtained at the patient’s original di-
agnosis and at the most recent diagnosis at relapse
were reviewed. The most recent biopsy specimen
was used to classify the type of lymphoma according
to the WHO classification system. The Follicular
Lymphoma International Prognostic Index (FLIPI)score was calculated based on the patient’s age,
disease stage, serum lactate dehydrogenase (LDH)
value, number of nodal sites, and hemoglobin level
immediately before transplantation [12]. These tests
were performed after salvage chemotherapy but be-
fore high-dose chemotherapy for pretransplantation
preparation. The response to transplantation was as-
sessed according to the original Cheson criteria [13].
These criteria were used prospectively from their in-
ception in 1998 and were applied retrospectively to
cases before that time. Chemosensitive disease was
defined as at least a partial response to the last che-
motherapy before transplantation. Each patient was
placed into 1 of 3 categories of transplantation regi-
men: (1) chemotherapy only, (2) chemotherapy with
total body irradiation (TBI), or (3) chemotherapy
with monoclonal antibody (mAb) therapy including
either unconjugated or radiolabeled anti-CD20 anti-
bodies.
Statistical Analysis
OS was defined as the time from transplantation to
death from any cause. PFS was defined as the time
from transplantation to documented progression/re-
lapse of lymphoma or death from any cause. Progres-
sion was defined as an increase in bidimensionally
measurable disease $ 50%, new lymph nodes $ 1.5
cm, or new sites of disease.
The univariate probability of progression was
estimated using cumulative incidence with nonprog-
ression mortality as the competing risk. The
probabilities of PFS and OS were estimated using
the Kaplan-Meier method [14]. Multivariate analysis
was performed using the Cox proportional hazards re-
gression method [15]. Proportionality was tested using
time-dependent covariates. Stepwise forward model
building was used, and covariates with a P value #
.05 were entered into the model. Interactions among
covariates were tested in the final model.
Variables evaluated included age, sex, ethnicity,
histological grade (follicular NHL grade [FL] 1 and
FL 2 vs FL 3), interval from diagnosis to transplanta-
tion (# 12 months vs. 12 months), stage before con-
ditioning regimen (in complete remission, stage I/II,
stage III/IV), bone marrow involvement at condition-
ing (yes or no), extranodal involvement at conditioning
(yes or no), LDH level at conditioning (normal or ele-
vated), disease state at conditioning (second complete
remission [CR2], primary induction failure sensitive/
untreated, relapse 1 sensitive/untreated, relapse 2 or
more), FLIPI score at transplant (low, 0/1; intermedi-
ate, 2; high,$ 3), number of previous chemotherapies
(1, 2, or $ 3) and type of conditioning regimen (che-
motherapy only, chemotherapy 1 total body irradia-
tion [TBI], or chemotherapy 1 monoclonal
antibodies).
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Variable n (%)/median (range)
n 248
Age, years 46 (20-67)
20-40 52 (21)
41-54 158 (64)
$ 55 38 (15)
Sex
Female 115 (46)
Male 133 (54)
Race/ethnicity
White, non-Hispanic 240 (96)
White, Hispanic 2 (1)
Black, non-Hispanic 3 (1)
Asian 1 (1)
Other 2 (1)
Histology type
FL 1 64 (26)
FL 2 98 (40)
FL 3 86 (35)
Interval from diagnosis to transplantation
# 1 year 59 (24)
. 1 year 189 (76)
Stage before conditioning
CR 49 (20)
Stage I or II 52 (21)
Stage III or IV 113 (46)
Unknown 34 (14)
Bone marrow involvement before
conditioning
No 152 (61)
Yes 81 (33)
Unknown 15 (6)
Extranodal involvement before
conditioning
No 135 (55)
Yes 90 (36)
Unknown 23 (9)
Lactate dehydrogenase level before
conditioning
Normal 178 (72)
Elevated 67 (27)
Unknown 3 (1)
Disease stage/sensitivity
CR1 8 (3)
CR2 or more 32 (13)
Primary induction failure (sensitive/
untreated)
84 (34)
Relapse 1 (sensitive/untreated) 69 (28)
Relapse 2 or more 32 (13)
Not evaluable 23 (9)
Number of previous chemotherapies
One 58 (23)
Two 108 (44)
Three or more 82 (33)
Conditioning regimen
Chemotherapy* 110 (44)
Chemotherapy† 1 TBI 99 (40)
Chemotherapy‡ 1monoclonal
antibodies
39 (16)
Median follow-up of survivors, months 72 (12-192)
MICE indicates mesna, ifosfamide, carboplatin, and etoposide;
BEAM, carmustine, etoposide, cytarabine, and melphalan;
BEAC, carmustine, etoposide, cytarabine, and cyclophospha-
mide; BECH, carmustine, etoposide, cyclophosphamide, and hy-
droxyurea; Cy/TBI, cyclophosphamide and TBI; Cy/Thio/TBI,RESULTS
Patient Characteristics
Selected patient characteristics are detailed in
Table 1. The median patient age was 46 years (range,
20 to 67 years). Sixty-four patients had FL1, 98
(40%) had FL 2, and 86 (35%) had FL 3. No patients
with transformed FL were included in this analysis.
Most of the patients (189 [76%]) underwent transplan-
tation more than 12 months from their original diag-
nosis. Patients had received a median of 2 previous
chemotherapy regimens, and 82% of the patients had
chemotherapy-sensitive disease at the time of trans-
plantation. Sixty-seven patients (27%) had an elevated
LDH at the time of transplantation, and 81 (35%) had
bone marrow (BM) involvement with NHL at the time
of transplantation. Eighty-eight patients (35%) had
a low-risk FLIPI score, 87 (35%) had an intermedi-
ate-risk FLIPI score, 37 (15%) had high-risk FLIPI
score, and 36 (15%) had a missing value, preventing
calculation of FLIPI score at the time of transplanta-
tion. The patients with a missing value were mostly
from the earlier years of the study; however, their other
characteristics and treatments received were identical
to the patients who underwent transplantation during
the same time period. A total of 110 patients received
a high-dose chemotherapy-only regimen, 99 patients
received a chemotherapy/TBI regimen, and 39 pa-
tients received a chemotherapy/mAb–based regimen.
Of the 39 patients who received mAb in their condi-
tioning regimen, and 4 (10%) had received mAb with
previous initial or salvage therapy.
Outcomes
The median follow-up of surviving patients was
6.0 years (range, 1.0 to 15.0 years). Of the 117 patients
who progressed (47%), 80 subsequently died, and 37
remained alive after progression. Thirty-three patients
(13%) died without NHL progression. The 5-year
PFS was 44%, and the 5-year OS was 63%. The distri-
bution of 5-year PFS by histological grade was 47%
FL 1, 49% FL 2, and 36% FL 3; that of 5-year OS
was 61% FL, 70% FL 2, and 57% FL 3 (Table 2). Pa-
tients were alive up to 15 years after the transplanta-
tion. A multivariate analysis of factors predicting for
cyclophosphamide thiotepa and TBI; Bexxar-BEAC, 131-iodine
tositumomab, carmustine, etoposide, cytarabine, and cyclophos-
phamide; Bexxar-BEAM, 131-iodine tositumomab, carmustine,
etoposide, cytarabine, and melphalan; Rituxan-BEAM, rituxi-
mab, carmustine, etoposide, cytarabine, and melphalan.
*Conditioning regimen includes MICE (n 5 1), BEAM (n 5 38),
BEAC (n 5 64), and BECH (n 5 7).
†Conditioning regimen includes Cy/TBI (n 5 98) and Cy/Thio/
TBI (n 5 1).
‡Conditioning regimen includes Bexxar-BEAC (n 5 2), Bexxar-
BEAM (n 5 4), and Rituxan-BEAM (n 5 33).
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performed.
Analysis of Prognostic Factors
The results of multivariate analysis for progres-
sion are given in Table 3. Variables increasing the
risk for lymphoma progression include having a FL
3 histology (P 5 .006), a high-risk FLIPI score at
Table 2. Univariate outcome probabilities, percent (95% CI)
Outcome 1 year 3 years 5 years
Progression* 22 (17-27) 37 (31-43) 46 (39-52)
PFS† 72 (66-78) 54 (48-60) 44 (37-50)
OS† 90 (85-93) 73 (67-79) 63 (56-69)
Outcome by histological grade FL 1 FL 2 FL 3
Progression*
1 year 25 (16-34) 18 (11-26) 23 (15-33)
3 years 35 (24-47) 34 (25-44) 41 (31-52)
5 years 41 (28-53) 45 (34-55) 50 (39-61)
PFS†
1 year 70 (57-80) 78 (69-85) 67 (56-76)
3 years 55 (41-66) 60 (50-69) 47 (36-57)
5 years 47 (34-59) 49 (38-59) 36 (25-47)
OS†
1 year 94 (84-98) 93 (86-96) 84 (74-90)
3 years 75 (61-84) 78 (68-85) 68 (56-76)
5 years 61 (47-73) 70 (59-78) 57 (45-67)
*Cumulative incidence.
†Kaplan-Meier estimate.
Table 3.Multivariate analysis for progression
Variable n
Relative risk
of progression
(95% CI) P value
Histological grade .01*
FL 1 64 1.00
FL 2 98 1.20 (0.73-1.98) .48
FL 3 86 2.14 (1.24-3.68) .006
FLIPI score
Low (0 or 1) 88 1.00
Intermediate (2) 87 1.17 (0.73-1.88) .52
High ($ 3) 37 2.13 (1.23-3.69) .007
Missing 36 1.20 (1.10-3.61) .02
Number of previous
chemotherapies
.008†
One 58 1.00
Two 108 1.62 (0.097-2.70) .06
Three or more 82 2.35 (1.36-4.04) .002
Conditioning regimen .004†
Chemotherapy 1 TBI 99 1.00
Chemotherapy alone 110 0.87 (0.57-1.31) .50
Chemotherapy 1
monoclonal
antibodies
39 0.35 (0.17-0.74) .006
*Two degrees of freedom test.
†Four degrees of freedom test.transplantation (P 5 .007), having received 3 or
more previous chemotherapy regimens before trans-
plantation (P 5 .002), and not having received an
mAb–based transplantation conditioning regimen
(P 5 .006).
Table 4 gives the multivariate analysis results for
PFS. Variables contributing to decreased PFS in-
cluded FL 3 histology (P 5 .004), a high-risk FLIPI
score (P5 .002), and having received 3 or more previ-
ous chemotherapy regimens (P\ .001). The same var-
iables were significant for OS, as shown in Table 5.
The patients with at least 1 value missing for the FLIPI
calculation behaved similarly to the high-risk FLIPI
patients. The probability of OS is shown by histolog-
ical grade (Figure 1), FLIPI score (Figure 2), and num-
ber of chemotherapy regimens before transplantation
Table 4. Multivariate analysis for PFS
Variable n
Relative risk of
treatment failure
(95% CI) P value
Histological grade .007*
FL 1 64 1.00
FL 2 98 1.21 (0.79-1.88) .38
FL 3 86 1.97 (1.24-3.12) .004
FLIPI score
Low (0 or 1) 88 1.00
Intermediate (2) 87 1.13 (0.74-1.72) .58
High ($ 3) 37 2.13 (1.32-3.45) .002
Missing 36 2.79 (1.70-4.60) \ .001
Number of previous
chemotherapies
.02†
One 58 1.00
Two 108 1.35 (0.87-2.10) .19
Three or more 82 1.92 (1.21-3.02) \ .001
*Two degrees of freedom test.
†Four degrees of freedom test.
Table 5. Multivariate analysis for OS
Variable n
Relative risk of
progression
(95% CI) P value
Histological grade .01*
FL 1 64 1.00
FL 2 98 1.13 (0.69-1.84) .63
FL 3 86 2.00 (1.18-3.39) .01
FLIPI score \ .001
Low (0 or 1) 88 1.00
Intermediate (2) 97 1.35 (0.80-2.28) .26
High ($ 3) 37 2.50 (1.43-4.37) .001
Missing 36 3.96 (2.23-7.05) \ .001
Number of previous
chemotherapies
\ .002†
One 58 1.00
Two 108 1.48 (0.84-2.60) .17
Three or more 82 3.00 (1.70-5.28) \ .001
*Two degrees of freedom test.
†Four degrees of freedom test.
40 J. M. Vose et al.(Figure 3). Patients who failed only 1 previous chemo-
therapy regimen before proceeding to stem cell trans-
plantation had a 5-year OS of 87% for FL 1, 72% for
FL2, and 77% for FL3 (Figure 4).
In addition, a new risk factor model was con-
structed using this information in an attempt to iden-
tify recurrent follicular NHL patients with the best
expected transplantation outcomes. A risk model was
formulated using the risk factors of FL3 histology,
a high-risk FLIPI score at transplantation, and 3 or
more previous chemotherapy regimens. The 5-year
probability of OS was 82% (95% confidence interval
[CI] 5 71%-90%) for patients with none of these
risk factors (n 5 78), 67% (95% CI 5 57%-76%) for
those with 1 risk factor (n 5 106), 36% (95% CI 5
22%-49%) for those with 2 risk factors (n 5 57), and
only 14% (95% CI 5 1%-46%) for those with all 3
of these risk factors (n 5 7) (Figure 5).
DISCUSSION
Although most patients with FL 1 and 2 NHL have
a relatively indolent course of disease, the disease is not
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Figure 1. OS survival based on WHO histological grade.
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Figure 2. OS based on FLIPI score.considered curable with standard chemotherapy [1-4].
Several studies have recently analyzed the changes in
treatment approaches over time and have identified
possible improvements in PFS and perhaps OS from
adding an mAb to the therapy [16-19]. High-dose che-
motherapy with autologous SCT is one option for pa-
tients with relapsed follicular NHL. Several studies of
autologous SCT in this patient population have dem-
onstrated improved disease-free survival (DFS) but no
consistent improvement in OS compared with a histor-
ically controlled population [6-9]. The only random-
ized trial reported to date (the CUP trial) was
conducted in Europe and randomized patients with re-
lapsed follicular NHL to standard chemotherapy, un-
purged autologous stem cell transplantation, or
purged transplantation [10]. In this trial, 140 patients
with relapsed, chemosensitive follicular NHL were
randomized to 1 of the 3 arms. The OS at 4 years
was 46% for the chemotherapy arm, 71% for the un-
purged transplantation arm, and 77% for the purged
transplantation arm. The 2-year PFS was 26% for
the chemotherapy arm, 58% for the unpurged trans-
plantation arm, and 55% for the purged transplanta-
tion arm. Significant reduction in the hazard rates for
both PFS and OS were seen when comparing the
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Figure 3. OS based on the number of previous chemotherapy regi-
mens received before transplantation.
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however, there was no difference between the 2 trans-
plantation arms. Although the accrual goal was not
met in the CUP trial, the trial did demonstrate
improved PFS and OS in the transplantation arms
over standard chemotherapy.
The next issue to be addressed is which follicular
NHL patient population would benefit the most
from high-dose chemotherapy and autologous stem
cell transplantation. Various studies have evaluated
the prognostic indicators that predict for better out-
come with autologous transplant for follicular NHL,
including chemotherapy sensitivity, bulk of disease,
number of previous chemotherapies received, and the
FLIPI [6-9]. Because it is relatively new, the FLIPI
has been less widely used in clinical trial evaluations
of transplantation. Our study has demonstrated a worse
outcome for patients with 3 or more previous chemo-
therapies, FL 3 disease, and a high FLIPI score at the
time of transplantation. Patients with all 3 of these
characteristics have a 5-year OS of only 14%, com-
pared with an 82% 5-year survival in patients with
none of these characteristics. This information should
be of assistance when considering autologous SCT for
patients before they have been heavily treated with
chemotherapy or have progressed to a higher grade
of follicular NHL. Therefore, standard autologous
SCT should not be considered solely as a last option
for follicular NHL patients who have failed all other
options, but rather should be considered earlier in
the course of disease, when the optimum benefit can
be realized.
This information needs to be placed into context
with the finding of clinical trials using other therapies,
such as immunotherapy with rituximab [20], radiola-
beled mAb [21,22], or other novel agents currently un-
der study in clinical trials [23,24]. Because few of the
patients in this retrospective analysis had received pre-
vious rituximab therapy, the use of an mAb in the
transplantation regimen may have improved the re-
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Figure 5.OS based on number of risk factors according to the prog-
nostic model index.sults over what would be seen in patients who
had received previous mAb therapy. However,
a retrospective analysis of diffuse large B cell lym-
phoma did not demonstrate a difference in outcome
of autologous transplantation in patients receiving
CHOP chemotherapy versus those receiving CHOP-
R (CHOP 1 rituximab) [25]. This question needs to
be addressed in recently treated follicular NHL pa-
tients with a history of rituximab therapy.
Without the benefit of large randomized trials, we
must consider the individual patient characteristics,
such as histological grade of the follicular NHL,
FLIPI score, type and number of previous therapies,
and the patient’s condition and individual preferences,
when weighing the choice of therapy for patients with
recurrent follicular NHL.
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